Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4 + T cells in the broncho-alveolar lavage of patients with systemic sclerosis

Clinical Immunology

Volumn 141, Issue 3, 2011, Pages 293-303

  Divekar, Anagha A ^a   Khanna, Dinesh ^a   Abtin, Fereidoun ^a   Maranian, Paul ^a   Saggar, Rajeev ^a   Saggar, Rajan ^a   Furst, Daniel E ^a   Singh, Ram Raj ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fibrosis; IL 4; Imatinib; Scleroderma; T cells

Indexed keywords

CD31 ANTIGEN; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMATINIB; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; RANTES;

ADULT; ARTICLE; BLOOD CELL COUNT; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY FUNCTION; LIVER FUNCTION; LUNG FIBROSIS; LUNG LAVAGE; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; URINALYSIS;

ADULT; ANTIGENS, CD; ANTIGENS, CD31; BRONCHOALVEOLAR LAVAGE FLUID; CD4-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HUMANS; INTERLEUKIN-4; LUNG; MALE; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SCLERODERMA, SYSTEMIC;

EID: 81355160303     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.08.010     Document Type: Article

References (45)

1. Atamas S.P., Yurovsky V.V., Wise R., Wigley F.M., Goter Robinson C.J., Henry P., Alms W.J., White B. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum. 1999, 42:1168-1178.
2. Huaux F., Liu T., McGarry B., Ullenbruch M., Phan S. Dual roles of IL-4 in lung injury and fibrosis. J. Immunol. 2003, 170:2083-2092.
3. Tashkin D.P., Elashoff R., Clements P.J., Goldin J., Roth M.D., Furst D.E., Arriola E., Silver R., Strange C., Bolster M., Seibold J.R., Riley D.J., Hsu V.M., Varga J., Schraufnagel D.E., Theodore A., Simms R., Wise R., Wigley F., White B., Steen V., Read C., Mayes M., Parsley E., Mubarak K., Connolly M.K., Golden J., Olman M., Fessler B., Rothfield N., Metersky M. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 2006, 354:2655-2666.
4. Wolf D., Rumpold H. A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours. Drug Saf. 2009, 32:1001-1015.
5. Dewar A.L., Zannettino A.C., Hughes T.P., Lyons A.B. Inhibition of c-fms by imatinib: expanding the spectrum of treatment. Cell Cycle 2005, 4:851-853.
6. Daniels C.E., Wilkes M.C., Edens M., Kottom T.J., Murphy S.J., Limper A.H., Leof E.B. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. 2004, 114:1308-1316.
7. Soria A., Cario-Andre M., Lepreux S., Rezvani H.R., Pasquet J.M., Pain C., Schaeverbeke T., Mahon F.X., Taieb A. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology 2008, 216:109-117.
8. Sfikakis P.P., Gorgoulis V.G., Katsiari C.G., Evangelou K., Kostopoulos C., Black C.M. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 2008, 47:735-737.
9. Magro L., Catteau B., Coiteux V., Bruno B., Jouet J.P., Yakoub-Agha I. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant. 2008, 42:757-760.
10. Kay J., High W.A. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008, 58:2543-2548.
11. Khanna D., Saggar R., Mayes M.D., Abtin F., Clements P.J., Maranian P., Assassi S., Singh R.R., Furst D.E. Open-label pilot trial of imatinib mesylate (Gleevec) in the treatment of systemic sclerosis-associated active interstitial lung disease (SSc-ILD). Arthritis Rheum. July 18, 2011, doi:10.1002/art.30548. [Electronic publication ahead of print].
12. Spiera R.F., Gordon J.K., Mersten J.N., Magro C.M., Mehta M., Wildman H.F., Kloiber S., Kirou K.A., Lyman S., Crow M.K. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann. Rheum. Dis. 2011, 70:1003-1009.
13. Gay S.E., Kazerooni E.A., Toews G.B., Lynch J.P., Gross B.H., Cascade P.N., Spizarny D.L., Flint A., Schork M.A., Whyte R.I., Popovich J., Hyzy R., Martinez F.J. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am. J. Respir. Crit. Care Med. 1998, 157:1063-1072.
14. Zisman D.A., Karlamangla A.S., Ross D.J., Keane M.P., Belperio J.A., Saggar R., Lynch J.P., Ardehali A., Goldin J. High-resolution chest computed tomography findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2007, 132:773-779.
15. Huang d.W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009, 37:1-13.
16. Huang d.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
17. Beissbarth T., Speed T.P. GOstat: find statistically overrepresented gene ontologies within a group of genes. Bioinformatics 2004, 20:1464-1465.
18. Franzblau A.N. A Primer of Statistics for Non-Statisticians 1958, Harcourt Brace, New York.
19. Tashkin D.P., Elashoff R., Clements P.J., Roth M.D., Furst D.E., Silver R.M., Goldin J., Arriola E., Strange C., Bolster M.B., Seibold J.R., Riley D.J., Hsu V.M., Varga J., Schraufnagel D., Theodore A., Simms R., Wise R., Wigley F., White B., Steen V., Read C., Mayes M., Parsley E., Mubarak K., Connolly M.K., Golden J., Olman M., Fessler B., Rothfield N., Metersky M., Khanna D., Li N., Li G. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am. J. Respir. Crit. Care Med. 2007, 176:1026-1034.
20. Goh N.S., Desai S.R., Veeraraghavan S., Hansell D.M., Copley S.J., Maher T.M., Corte T.J., Sander C.R., Ratoff J., Devaraj A., Bozovic G., Denton C.P., Black C.M., du Bois R.M., Wells A.U. Interstitial lung disease in systemic sclerosis: a simple staging system. Am. J. Respir. Crit. Care Med. 2008, 177:1248-1254.
21. Remy-Jardin M., Giraud F., Remy J., Copin M.C., Gosselin B., Duhamel A. Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 1993, 189:693-698.
22. Beon M., Harley R.A., Wessels A., Silver R.M., Ludwicka-Bradley A. Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis. Clin. Exp. Rheumatol. 2004, 22:733-742.
23. Sawaya H.H., de Souza R.B., Carrasco S., Goldenstein-Schainberg C. Altered adhesion molecules expression on peripheral blood mononuclear cells from patients with systemic sclerosis and clinical correlations. Clin. Rheumatol. 2009, 28:847-851.
24. Boin F., De Fanis U., Bartlett S.J., Wigley F.M., Rosen A., Casolaro V. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum. 2008, 58:1165-1174.
25. Hussein M.R., Hassan H.I., Hofny E.R., Elkholy M., Fatehy N.A., Abd Elmoniem A.E., Ezz El-Din A.M., Afifi O.A., Rashed H.G. Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J. Clin. Pathol. 2005, 58:178-184.
26. Schmidt K., Martinez-Gamboa L., Meier S., Witt C., Meisel C., Hanitsch L.G., Becker M.O., Huscher D., Burmester G.R., Riemekasten G. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res. Ther. 2009, 11:R111.
27. Garcia J.G., Wolven R.G., Garcia P.L., Keogh B.A. Assessment of interlobar variation of bronchoalveolar lavage cellular differentials in interstitial lung diseases. Am. Rev. Respir. Dis. 1986, 133:444-449.
28. Flaherty K.R., Travis W.D., Colby T.V., Toews G.B., Kazerooni E.A., Gross B.H., Jain A., Strawderman R.L., Flint A., Lynch J.P., Martinez F.J. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2001, 164:1722-1727.
29. Hamilton R.F., Parsley E., Holian A. Alveolar macrophages from systemic sclerosis patients: evidence for IL-4-mediated phenotype changes. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286:L1202-L1209.
30. Huaux F., Liu T., McGarry B., Ullenbruch M., Xing Z., Phan S. Eosinophils and T lymphocytes possess distinct roles in bleomycin-induced lung injury and fibrosis. J. Immunol. 2003, 171:5470-5481.
31. Shimizu Y., Kuwabara H., Ono A., Higuchi S., Hisada T., Dobashi K., Utsugi M., Mita Y., Mori M. Intracellular Th1/Th2 balance of pulmonary CD4(+) T cells in patients with active interstitial pneumonia evaluated by serum KL-6. Immunopharmacol. Immunotoxicol. 2006, 28:295-304.
32. Mavalia C., Scaletti C., Romagnani P., Carossino A., Pignone A., Emmi L., Pupilli C., Pizzolo G., Maggi E., Romagnani S. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am. J. Pathol. 1997, 151:1751-1758.
33. Hattori N., Degen J.L., Sisson T.H., Liu H., Moore B.B., Pandrangi R.G., Simon R.H., Drew A.F. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J. Clin. Invest. 2000, 106:1341-1350.
34. Moschen A.R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 2007, 178:1748-1758.
35. P.F. Piguet, a, C. Vesina, G.E. Graua, R.C. Thompsonb, Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica, Cytokine, 5.
36. Franzke A., Piao W., Lauber J., Gatzlaff P., Konecke C., Hansen W., Schmitt-Thomsen A., Hertenstein B., Buer J., Ganser A. G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood 2003, 102:734-739.
37. Hill G.R., Olver S.D., Kuns R.D., Varelias A., Raffelt N.C., Don A.L., Markey K.A., Wilson Y.A., Smyth M.J., Iwakura Y., Tocker J., Clouston A.D., Macdonald K.P. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood 2010, 116:819-828.
38. ten Freyhaus H., Dumitrescu D., Bovenschulte H., Erdmann E., Rosenkranz S. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin. Res. Cardiol. 2009, 98:265-267.
39. Chung L., Fiorentino D.F., Benbarak M.J., Adler A.S., Mariano M.M., Paniagua R.T., Milano A., Connolly M.K., Ratiner B.D., Wiskocil R.L., Whitfield M.L., Chang H.Y., Robinson W.H. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum. 2009, 60:584-591.
40. Paniagua R.T., Sharpe O., Ho P.P., Chan S.M., Chang A., Higgins J.P., Tomooka B.H., Thomas F.M., Song J.J., Goodman S.B., Lee D.M., Genovese M.C., Utz P.J., Steinman L., Robinson W.H. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest. 2006, 116:2633-2642.
41. Seggewiss R., Lore K., Greiner E., Magnusson M.K., Price D.A., Douek D.C., Dunbar C.E., Wiestner A. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005, 105:2473-2479.
42. Gao H., Lee B.N., Talpaz M., Donato N.J., Cortes J.E., Kantarjian H.M., Reuben J.M. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 2005, 19:1905-1911.
43. Sato S., Komura K., Hasegawa M., Fujimoto M., Takehara K. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc. J. Rheumatol. 2001, 28:2460-2465.
44. Bjerke R.D., Tashkin D.P., Clements P.J., Chopra S.K., Gong H., Bein M. Small airways in progressive systemic sclerosis (PSS). Am. J. Med. 1979, 66:201-209.
45. Guttadauria M., Ellman H., Emmanuel G., Kaplan D., Diamond H. Pulmonary function in scleroderma. Arthritis Rheum. 1977, 20:1071-1079.